Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC.ACHV · Entity 5072 | Director | September 04, 2025 | September 08, 2025 |
| TFF Pharmaceuticals, Inc.TFFP · Entity 89110 | Director | July 03, 2024 | July 08, 2024 |
| VIVUS INCVVUS · Entity 151460 | Director | February 20, 2020 | February 24, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACHIEVE LIFE SCIENCES, INC.
Report date September 04, 2025 · Filed September 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 315,142 |
Ending reported balance
After 2025-09-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-09-04 · Exercise / conversion · Acquired 455,000 · Balance 455,000 F1: Represents shares of common stock acquired upon settlement of the performance restricted stock units ("PRSUs") listed in Table II. Row 2 · 2025-09-04 · Sale · Disposed 139,858 · Balance 315,142 F2: Represents shares of common stock that have been sold by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the PRSUs. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.68 to $2.88 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Performance Restricted Stock Unit (PRSU)SEC Table II · derivative / convertible security · Expires 2029-01-13 | Direct | 0 |
Reported balance
After 2025-09-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-09-04 · Exercise / conversion · Disposed 455,000 · Balance 0 F4: Represents PRSUs previously reported on January 14, 2025 that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors. F5: Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement. F6: Pursuant to the terms of the award agreement governing the PRSU, the total number of shares underlying the PRSU vest on the achievement of one of certain milestones. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock acquired upon settlement of the performance restricted stock units ("PRSUs") listed in Table II.
F2: Represents shares of common stock that have been sold by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the PRSUs.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.68 to $2.88 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: Represents PRSUs previously reported on January 14, 2025 that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors.
F5: Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement.
F6: Pursuant to the terms of the award agreement governing the PRSU, the total number of shares underlying the PRSU vest on the achievement of one of certain milestones.
TFF Pharmaceuticals, Inc.
Report date July 03, 2024 · Filed July 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,583 |
Reported balance
After 2024-07-03 transaction · row 1
1 source rowRow 1 · 2024-07-03 · Grant · Acquired 1,583 · Balance 1,583 F1: Represents shares of common stock underlying restricted stock units ("RSUs"). Each RSU entitles its holder to receive one share of common stock of the issuer. The RSUs vest and settle in full on June 19, 2025. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.82 · Expires 2034-07-03 | Direct | 1,583 |
Reported balance
After 2024-07-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-07-03 · Grant · Acquired 1,583 · Balance 1,583 F2: Options vest in full on June 19, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying restricted stock units ("RSUs"). Each RSU entitles its holder to receive one share of common stock of the issuer. The RSUs vest and settle in full on June 19, 2025.
F2: Options vest in full on June 19, 2025.
VIVUS INC
Report date February 20, 2020 · Filed February 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.41 | Direct | 15,000 |
Reported balance
After 2020-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-20 · Grant · Acquired 15,000 · Balance 15,000 F1: One twelfth (1/12th) of the total number of shares underlying the option vest and become exercisable on the monthly anniversary date following June 5, 2019, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2018 Equity Incentive Plan) on the relevant vesting dates. F2: The option expires on the earlier of (a) February 20, 2027 and (b) the six (6) month anniversary of the date the reporting person ceases to be a Service Provider. |
Filing footnotes · ownership attribution and instrument terms
F1: One twelfth (1/12th) of the total number of shares underlying the option vest and become exercisable on the monthly anniversary date following June 5, 2019, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2018 Equity Incentive Plan) on the relevant vesting dates.
F2: The option expires on the earlier of (a) February 20, 2027 and (b) the six (6) month anniversary of the date the reporting person ceases to be a Service Provider.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Satsuma Pharmaceuticals, Inc.
Report date June 08, 2023 · Filed June 08, 2023
Section 16 reporting ended · disclosed 2023-06-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.99 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.60 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.46 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-08 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.56 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-06-08 · Disposition to issuer · Disposed 14,893 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-06-08 · Disposition to issuer · Disposed 12,765 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.90 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-06-08 · Disposition to issuer · Disposed 12,765 · Balance 0 F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes.
F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2025 Filed Sep 8, 2025 20:54 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionPerformance Restricted Stock Unit (PRSU) · Derivative | 455,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-113591 · ownership.xml · derivative · entry 3 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 455,000 shares Expires 2029-01-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Represents PRSUs previously reported on January 14, 2025 that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors. F5 · derivative.exercise_price: Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement. F6 · derivative.exercise_date: Pursuant to the terms of the award agreement governing the PRSU, the total number of shares underlying the PRSU vest on the achievement of one of certain milestones. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 20:54 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | SaleCommon Stock | 139,858 | $2.77 | $387,406.66 |
DisclosureSEC source: 0000950170-25-113591 · ownership.xml · nonDerivative · entry 2 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 315,142 F2 · shares: Represents shares of common stock that have been sold by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the PRSUs. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.68 to $2.88 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 20:54 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | Exercise / conversionCommon Stock | 455,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-113591 · ownership.xml · nonDerivative · entry 1 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 455,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock acquired upon settlement of the performance restricted stock units ("PRSUs") listed in Table II. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:48 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 31,500 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0000950170-25-084415 · ownership.xml · derivative · entry 1 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2035-06-06 F1 · derivative.exercise_date: The options vest 100% on the earlier of June 6, 2026 or the date immediately prior to the Issuer's 2026 annual meeting of stockholders. Read SEC document |
| January 13, 2025 Filed Jan 14, 2025 21:42 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 195,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0000950170-25-005392 · ownership.xml · derivative · entry 2 KING THOMAS BRAXTON · CIK 0001279309 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2035-01-13 F3 · derivative.exercise_date: The option will vest as to 1/4 of the total award on the first anniversary of August 26, 2024, and thereafter in substantially equal monthly installments over 36 months, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 13, 2025 Filed Jan 14, 2025 21:42 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantPerformance Restricted Stock Unit (PRSU) · Derivative | 455,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-005392 · ownership.xml · derivative · entry 1 KING THOMAS BRAXTON · CIK 0001279309 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 455,000 Underlying: Common Stock · 455,000 shares Expires 2029-01-13 F1 · derivative.exercise_price: Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement. F2 · derivative.exercise_date: Pursuant to the terms of the award agreement governing the PRSU, the total number of shares underlying the PRSU vest on the achievement of one of certain milestones being met. The PRSUs will lapse in full if achievement of at least one of the milestones is not met. Read SEC document |
| July 03, 2024 Filed Jul 8, 2024 17:40 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | GrantStock Options (Right to Buy) · Derivative | 1,583 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001213900-24-059871 · ownership.xml · derivative · entry 2 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,583 Underlying: Common stock · 1,583 shares Expires 2034-07-03 F2 · derivative.exercise_date: Options vest in full on June 19, 2025. Read SEC document |
| July 03, 2024 Filed Jul 8, 2024 17:40 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | GrantCommon Stock | 1,583 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-059871 · ownership.xml · nonDerivative · entry 1 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,583 F1 · shares: Represents shares of common stock underlying restricted stock units ("RSUs"). Each RSU entitles its holder to receive one share of common stock of the issuer. The RSUs vest and settle in full on June 19, 2025. Read SEC document |
| April 18, 2024 Filed Apr 22, 2024 20:53 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | GrantRestricted stock units · Derivative | 3,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-035085 · ownership.xml · derivative · entry 1 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,110 Underlying: Common stock · 3,110 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit, or RSU, represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs were awarded to the Reporting Person in lieu of their quarterly cash director fee for the first quarter of 2024. The settlement of the RSUs is contingent on stockholder approval, at the Issuer's 2024 annual meeting of stockholders, or Annual Meeting, of an amendment to increase the share reserve under the Issuer's 2021 Stock Incentive Plan, or 2021 Plan. The RSUs shall terminate if the Issuer's stockholders do not approve the proposed amendment to the 2021 Plan at the Annual Meeting. Subject to stockholder approval of the amendment to the 2021 Plan, and subject further to the consummation of the Issuer's next equity financing, the RSUs will settle in four equal installments, with the first installment settling on completion of the Issuer's next equity financing and the other three installments settling on the 15th, 30th and 45th day following the completion of the next equity financing. F2 · derivative.expiration_date: The RSUs were awarded to the Reporting Person in lieu of their quarterly cash director fee for the first quarter of 2024. The settlement of the RSUs is contingent on stockholder approval, at the Issuer's 2024 annual meeting of stockholders, or Annual Meeting, of an amendment to increase the share reserve under the Issuer's 2021 Stock Incentive Plan, or 2021 Plan. The RSUs shall terminate if the Issuer's stockholders do not approve the proposed amendment to the 2021 Plan at the Annual Meeting. Subject to stockholder approval of the amendment to the 2021 Plan, and subject further to the consummation of the Issuer's next equity financing, the RSUs will settle in four equal installments, with the first installment settling on completion of the Issuer's next equity financing and the other three installments settling on the 15th, 30th and 45th day following the completion of the next equity financing. Read SEC document |
| January 22, 2024 Filed Jan 25, 2024 00:22 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 31,500 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-24-002207 · doc4.xml · derivative · entry 1 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2034-01-22 F1 · derivative.exercise_date: The options vest 100% on the earlier of 18 months from the grant date or the date immediately prior to the Issuer's 2025 annual meeting of stockholders. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 16:08 UTC | TFF Pharmaceuticals, Inc. TFFP · Entity 89110 | GrantStock Options (Right to Buy) · Derivative | 132,442 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001213900-23-096082 · ownership.xml · derivative · entry 1 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,442 Underlying: Common Stock · 132,442 shares Expires 2033-12-13 F1 · derivative.exercise_date: The options vest and first become exercisable in 36 equal monthly installments, with the first installment vesting on December 13, 2024 and the remaining installments on the 13th of the month for the next 35 months. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 16:30 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 12,765 | Not disclosed Strike: $0.90 | Not disclosed |
DisclosureSEC source: 0000899243-23-014876 · doc4.xml · derivative · entry 6 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,765 shares Expires not disclosed F1 · price: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F1 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F1 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 16:30 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 12,765 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0000899243-23-014876 · doc4.xml · derivative · entry 5 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,765 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F1 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F1 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 16:30 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 14,893 | $0.00 Strike: $4.56 | $0.00 |
DisclosureSEC source: 0000899243-23-014876 · doc4.xml · derivative · entry 4 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,893 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F1 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F1 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 16:30 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0000899243-23-014876 · doc4.xml · derivative · entry 3 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F1 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F1 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 16:30 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0000899243-23-014876 · doc4.xml · derivative · entry 2 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F1 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F1 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| June 08, 2023 Filed Jun 8, 2023 16:30 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.99 | $0.00 |
DisclosureSEC source: 0000899243-23-014876 · doc4.xml · derivative · entry 1 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and canceled immediately prior to the Effective Time for no consideration. F1 · derivative.exercise_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. F1 · derivative.expiration_date: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. Read SEC document |
| March 29, 2023 Filed Mar 30, 2023 15:27 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001209191-23-021585 · doc4.xml · derivative · entry 1 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2033-03-29 F1 · derivative.exercise_date: The options vest on the one month anniversary of March 29, 2023 and thereafter in monthly installments over 36 months. Read SEC document |
| March 29, 2023 Filed Jun 9, 2023 20:15 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 23,250 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001209191-23-035787 · doc4.xml · derivative · entry 1 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,250 Underlying: Common Stock · 23,250 shares Expires 2033-03-29 F1 · derivative.exercise_date: These options were granted on March 29, 2023 (the "Grant Date") pursuant to the 2023 Non-Employee Director Equity Incentive Plan (the "Plan"), subject to the Plans approval by the Issuers stockholders. The Plan was approved by the Issuers stockholders at the Issuers 2023 Annual Meeting of Stockholders on June 7, 2023. These options will vest on the one month anniversary of the Grant Date and thereafter in monthly installments over 36 months. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 17:34 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001567619-22-012468 · doc1.xml · derivative · entry 1 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-02 F1 · derivative.exercise_date: The option shall vest in full and become exercisable on the day immediately preceding the 2023 Annual Meeting. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 18:07 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001567619-20-020724 · doc1.xml · derivative · entry 1 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-12-03 F1 · derivative.exercise_date: The option shall vest in full and become exercisable on the day immediately preceding the 2022 Annual Meeting. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 19:24 UTC | Satsuma Pharmaceuticals, Inc. STSA · Entity 112442 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $26.99 | $0.00 |
DisclosureSEC source: 0001567619-20-012249 · doc1.xml · derivative · entry 1 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-11 F1 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the first Annual Meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Board through the applicable vesting date. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 18:06 UTC | VIVUS INC VVUS · Entity 151460 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001123292-20-000324 · edgar.xml · derivative · entry 1 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_date: One twelfth (1/12th) of the total number of shares underlying the option vest and become exercisable on the monthly anniversary date following June 5, 2019, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2018 Equity Incentive Plan) on the relevant vesting dates. F2 · derivative.expiration_date: The option expires on the earlier of (a) February 20, 2027 and (b) the six (6) month anniversary of the date the reporting person ceases to be a Service Provider. Read SEC document |
| October 26, 2018 Filed Oct 29, 2018 19:49 UTC | VIVUS INC VVUS · Entity 151460 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001123292-18-001042 · edgar.xml · derivative · entry 1 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_date: One twelfth (1/12th) of the total number of shares underlying the option vest and become exercisable on the 26th of each month following October 26, 2018, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2018 Equity Incentive Plan) on the relevant vesting dates. F2 · derivative.expiration_date: The option expires on the earlier of (a) October 26, 2025 and (b) the six (6) month anniversary of the date the reporting person ceases to be a Service Provider. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 16:15 UTC | VIVUS INC VVUS · Entity 151460 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001123292-18-000819 · edgar.xml · derivative · entry 1 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · derivative.expiration_date: The option expires on the earlier of (a) June 15, 2025 or (b) the twelve month anniversary of the date the reporting person ceases to be a Service Provider (as defined in the Issuer's 2010 Equity Incentive Plan). Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 18:37 UTC | VIVUS INC VVUS · Entity 151460 | GrantEmployee Stock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001123292-18-000244 · edgar.xml · derivative · entry 1 KING THOMAS BRAXTON · CIK 0001279309 · Director · Interim Chief Executive Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires not disclosed F1 · derivative.exercise_date: One thirty-sixth (1/36) of the total number of shares underlying the option vest on the last day of each month, beginning January 31, 2018, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2010 Equity Incentive Plan) on the relevant vesting dates. F2 · derivative.expiration_date: The option expires on the earlier of (a) January 26, 2025 or (b) the twelve (12) month anniversary of the date the reporting person ceases to be a Service Provider (as defined in the Issuer's 2010 Equity Incentive Plan). Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 20:28 UTC | VIVUS INC VVUS · Entity 151460 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001123292-17-001329 · edgar.xml · derivative · entry 1 KING THOMAS BRAXTON · CIK 0001279309 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2024-07-27 F1 · derivative.exercise_date: One eighteenth (1/18) of the total number of shares underlying the option were fully vested on the date of grant, and one thirty-sixth (1/36) of the total number of shares underlying the option vest on the 24th of each month, beginning on August 24, 2017, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2010 Equity Incentive Plan) on the relevant vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.